ESTRO 2023 | HypoG01:UNICANCER phase 3 trial of locoregional hypo vs normo fractionated RT in early breast cancer

Sofia Rivera, MD, PhD, Gustave Roussy, Villejuif, France, provides an overview of the the Phase III HypoG-01 (NCT03127995) trial compared hypofractionated (HF) radiation therapy (RT) with normofractionated (NF) RT in loco-regional early breast cancer (EBC) to assess the risk of arm lymphedema. The study included 1,221 patients who received either HF RT (40 Gy/15 fr) or NF RT (50 Gy/25 fr). The primary endpoint was the occurrence of arm lymphedema after RT. The results showed that HF RT was non-inferior to NF RT in terms of lymphedema risk, with a 3-year rate of 24.1% in the HF group and 22.6% in the NF group. The study provides level 1A evidence supporting the use of 40 Gy/15 fr for loco-regional radiation therapy in EBC to minimize the risk of arm lymphedema. This interview took place at the ESTRO congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.